ACE2 and COVID-19: Overall, the impairment of the innate immune response with a combined reduced type I IFN response, and ACE2 activity in the lungs, could contribute to the high levels of pro-inflammatory cytokines and chemokines released, promoting inflammation, vascular permeability, and poor outcomes in older COVID-19 patients (91).